Shares of PTC Therapeutics (PTCT) are higher in Tuesday trading (March 31, 2026), with traders pointing to renewed confidence in the company’s near-term commercial execution—especially the Sephience (sepiapterin) launch in phenylketonuria (PKU)—after recent disclosures highlighting meaningful early patient uptake and revenue contribution. Recent company commentary has emphasized a growing treated-patient base and expanding launch footprint, which is supportive for sentiment after prior volatility tied to guidance and model resets.

A key underpinning for the bid is Sephience’s commercial trajectory: PTC has recently disclosed that hundreds of patients were on commercial Sephience therapy globally and that U.S. patient start activity has been building, alongside a notable Q4 revenue figure for the product. With Sephience positioned as a foundational growth driver, incremental signs of sustained demand and conversion can disproportionately influence the stock, given investor sensitivity to durability of the launch curve and payer dynamics.

Today’s strength also appears consistent with a risk-on tone in biotech/rare-disease equities, where changing expectations around FDA posture and leadership have recently supported broader multiple expansion and “approval odds” repricing across parts of the space. In that context, PTCT can trade as both a company-specific commercial story and a read-through beneficiary of improved regulatory sentiment.

Near-term, investors will watch for additional updates on Sephience net sales progression, country-by-country rollout, and any signals on 2026 profitability/cash-flow trajectory. On the pipeline side, any incremental regulatory or clinical clarity that reduces timeline uncertainty could amplify moves, while any evidence of slower patient conversion, tougher reimbursement, or revised outlook assumptions would likely reintroduce volatility.